Charter offers ResearchChannel programming on VOD

August 15, 2006

St. Louis, Mo. -- All of Charter Communications' video on demand-enabled digital customers now have access to ResearchChannel's programming. ResearchChannel, a nonprofit media and technology organization, connects a global audience with the research and academic institutions whose developments, insights and discoveries affect our lives and futures.

"Special-interest programming like ResearchChannel is what is so great about VOD," said Jeff Jay, Charter's vice president of Product Development. "Leading-edge research is now available to Charter customers any time by way of video on demand. Remarkable speakers', researchers' and professors' revolutionary thoughts and discoveries can be accessed any time."

The Johns Hopkins University, the University of Washington and Howard Hughes Medical Institute are just a few of the world-renowned institutions that participate in ResearchChannel and whose programs will be featured on Charter VOD.

Charter has launched ResearchChannel to digital customers in all of its VOD-enabled service areas throughout the country. The entire ResearchChannel video library -- over 3,000 titles -- is available online at

"The goal of the world-class institutions that are part of ResearchChannel is to share research and scientific thinking on a panoply of subjects with as wide an audience as possible. Charter VOD brings this unique opportunity to a new audience. Through lectures, interviews and documentaries, viewers will hear firsthand, directly from researchers at leading institutions," said Amy Philipson, executive director of ResearchChannel.

One of the initial programs available on demand is the University of Virginia's "Faith, Certainty, and the Presidency of George W. Bush," in which author and journalist Ron Suskind unravels mysteries of the Bush administration. Another is "New Tests, New Treatments, Better Outcomes for Patients with Colorectal Cancer," from Stanford University Medical Center, which explains significant gains in the prevention, diagnosis and treatment of colorectal cancer.

VOD viewers will also be able to watch legendary CBS anchorman Walter Cronkite in "A Conversation with Walter Cronkite," produced by the University of Southern California. Another program is "Google: A Behind-the-Scenes Look," in which Jeff Dean talks about the importance of search on the Internet and the challenges it poses in computer science.
About Charter Communications
Charter Communications Inc. is a leading broadband communications company and the third-largest publicly traded cable operator in the United States. Charter provides a full range of advanced broadband services, including advanced digital video entertainment programming (Charter DigitalTM), Charter High-SpeedTM Internet access service and Charter TelephoneTM services. Charter BusinessTM similarly provides scalable, tailored and cost-effective broadband communications solutions to business organizations, such as business-to-business Internet access, data networking and video and music entertainment services. Charter's advertising sales and production services are sold under the Charter Media® brand. More information about Charter can be found at

About ResearchChannel
ResearchChannel is a nonprofit media and technology organization that connects a global audience with the research and academic institutions whose developments, insights and discoveries affect our lives and futures. ResearchChannel was founded in 1996 by leading research and academic institutions so they could share the work of their researchers with the public while collectively participating in advanced distribution and interactive technology experiments. Programs are shared in their original form, unmediated and without interruption. Today, more than 50 institutions participate as members and affiliates, and that number continues to grow. More information about ResearchChannel can be found at


Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to